A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective

BACKGROUND: Dickkopf-related protein 3 (DKK3) is a secreted protein that is involved in the regulation of cardiac remodeling and vascular smooth muscle cell differentiation, but little is known about its role in atherosclerosis.

METHODS: We tested the hypothesis that DKK3 is atheroprotective using both epidemiological and experimental approaches. Blood DKK3 levels were measured in the Bruneck Study in 2000 (n=684) and then in 2005 (n=574). DKK3-deficient mice were crossed with apolipoprotein E−/− mice to evaluate atherosclerosis development and vessel injury-induced neointimal formation. Endothelial cell migration and the underlying mechanisms were studied using in vitro cell culture models.

RESULTS: In the prospective population-based Bruneck Study, the level of plasma DKK3 was inversely related to carotid artery intima-media thickness and 5-year progression of carotid atherosclerosis independently from standard risk factors for atherosclerosis. Experimentally, we analyzed the area of atherosclerotic lesions, femoral artery injury-induced reendothelialization, and neointima formation in both DKK3−/− apolipoprotein E−/− and DKK3+/+ apolipoprotein E−/− mice. It was demonstrated that DKK3 deficiency accelerated atherosclerosis and delayed reendothelialization with consequently exacerbated neointima formation. To explore the underlying mechanisms, we performed transwell and scratch migration assays using cultured human endothelial cells, which exhibited a significant induction in cell migration in response to DKK3 stimulation. This DKK3-induced migration activated ROR2 and DVL1, activated Rac1 GTPases, and upregulated JNK and c-jun phosphorylation in endothelial cells. Knockdown of the ROR2 receptor using specific siRNA or transfection of a dominant-negative form of Rac1 in endothelial cells markedly inhibited cell migration and downstream JNK and c-jun phosphorylation.

CONCLUSIONS: This study provides the evidence for a role of DKK3 in the protection against atherosclerosis involving endothelial migration and repair, with great therapeutic potential implications against atherosclerosis.
Atherosclerosis is characterized by endothelial dysfunction, inflammation, progressive lipid deposition, and vessel stiffness, with potential complications such as myocardial infarction or stroke. The endothelium, as a crude restrictive barrier of the vessel wall, can protect the vessel from inflammation. Once endothelial cells are impaired, they will become the initial sensors of a complex cascade of events. Many studies have demonstrated that the underlying pathophysiology of atherosclerosis is initiated by endothelial dysfunction, which is caused by physical or chemical offenses such as hypertension, shear stress of disturbed laminar flow, reactive oxygen species in the circulation, decreased nitric oxide bioactivity, and hyperglycemia. These factors can directly or indirectly induce endothelial dysfunction/death in arteries, followed by cell regeneration in situ. In this process, neighboring endothelial cells have been proven to contribute to reendothelialization by migration and proliferation. In previous studies, vascular endothelial growth factor has been identified as a potent soluble factor for acceleration of reendothelialization and prevention of neointima formation. However, whether some novel soluble molecules are also playing a role in endothelial repair remains under investigation. In the present study, we take advantage of relevant human samples, transgenic animals, and in vitro cell biology models to elucidate the potential impact of DKK3 in atherosclerosis. In humans, we observed an inverse correlation between blood DKK3 level and development of atherosclerosis. In addition, we utilized genetic knockout mouse models combined with apolipoprotein E (ApoE−/−) mouse to assess the effects of DKK3 on atherosclerosis, reendothelialization, and neointima formation after femoral artery injury. We found that DKK3 promoted reendothelialization and inhibited lesion formation in DKK3+/−ApoE−/− mice. Our in vitro studies also revealed that DKK3 can induce endothelial cell migration by noncanonical Wnt signaling pathway.

**METHODS**

An expanded Methods is available in the online-only Data Supplement.

**Study Population**

Population recruitment was performed as part of the prospective community-based Bruneck Study. The survey area was located in the north of Italy (Bolzano Province). Special features of the study design and protocol have been described previously in detail and are provided in the online-only Data Supplement. The current study focused on the evaluation in 2000 (n=684) and follow-up between 2000 and 2005. The appropriate ethics committees approved the study protocol, and all study subjects gave their written informed consent before entering the study.

**Enzyme-Linked Immunosorbent Assay (ELISA) for Plasma DKK3**

The levels of DKK3 in human plasma were detected using an R&D DKK3 ELISA kit (R&D, DY1118). DKK1 levels were measured in serum with a commercial ELISA (Biomedica): Intra- and interassay coefficients of variation were low at 3% each, and the lower detection limit was 1.6 pmol/L.

**Animals**

All animal experiments were performed according to the protocols approved by the Institutional Committee for the Use and Care of Laboratory Animals. ApoE−/− mice were purchased from Jackson Laboratory. DKK3+/− mice were generated as...
described previously. Three genotypes of DKK3−/−, DKK3+/−, and DKK3+/+ mice were identified using PCR (primers: 5′-GATAGCTTCGAGACAC-3′, 5′-TCCATCAACCTCTCCA CCTCT-3′, 5′-TAAGTTGGGTACAGGCGG-3′, 5′-TAAGTTGGGTACAGGCGG-3′). ApoE−/− mice were crossed with DKK3−/− mice in our laboratory, and heterozygous offsprings were mated to produce ApoE−/− mice lacking DKK3 (DKK3−/− ApoE−/−). The genetic background of all mice used in the present study was C57BL/6.

**Creation of Chimeric Mice**

The procedure used for creating chimeric mice was similar to previously described. In brief, bone marrow transplantation was carried out on the DKK3−/− and DKK3+/− mice separately. Bone marrow cells were obtained from the femurs and tibias of either DKK3−/− or DKK3+/− mice (donors) and injected (1×10^7 cells in 0.2 mL) into the tail veins of the 6- to 8-week-old DKK3−/− or DKK3+/− mice (recipients), which received lethal irradiation (950 Rads) before. The measurement of DKK3 level in peripheral blood was performed 3 weeks after bone marrow transplantation.

**Tissue Harvesting and Lesion Analysis**

Mice were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg b.w.). Blood was obtained from inferior vena cava for lipid analysis. The heart was harvested intact and stored immediately in liquid nitrogen, and the whole length of the aorta was stored in formalin at 4°C. Then 8-μm-thick frozen sections were obtained from the heart and stained with oil Red O as described elsewhere. Aortas were opened longitudinally and fixed on a silicon bed with stainless steel pins (Fine Science Tool) with the intima exposed. Oil Red O staining was performed. Lesion areas were measured and quantified using a computer software AxioVision as described previously.

**Transwell Chemotaxis Assay**

Migration chemotaxis assay was performed by applying 24-well Boyden chambers with 8-μm pore size polycarbonate membranes (Corning) as described previously. Human umbilical vein endothelial cells (HUVECs) were seeded onto the upper chamber at 1×10^5 cells in 0.1% FBS EBM-2 basal medium, while the bottom chamber contained either 0.1% FBS EBM-2 basal medium with indicated concentrations of recombinant human DKK3 or Adeno-DKK3-HA/Adeno-CMV null overexpressed CHO cells supernatant. 0.1% FBS EBM-2 basal medium served as negative control for the comparison with recombinant human DKK3. After incubation for 6 hours at 37°C, the cells remaining on the upper side of the filters were removed by a cotton swab. The migrated cells on the underside of the membrane were fixed with 4% paraformaldehyde before staining with 0.1% crystal violet solution for 15 minutes. Data were expressed as the fold of migrated HUVECs compared to their corresponding controls.

**Statistical Analysis**

**Population Study**

The data were analyzed using the SPSS 24 software package. Levels of variables according to DKK3 tertile groups were presented as mean values ± SD or as medians with corresponding 25th and 75th percentiles (continuous variables) and percentages (dichotomous variables). Associations between DKK3 level (predictor variable) and vascular risk factors, lifestyle and demographic variables, intima-media thickness (IMT), and atherosclerosis progression were assessed using linear and logistic regression analysis. Levels of C-reactive protein and triglycerides were loge-transformed to satisfy the assumption of normality and constant variance of the residuals. The multivariate models focusing on IMT or atherosclerosis progression included the following covariates: age (years), sex (female, male), smoking (cigarettes per day), hypertension, high- and low-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, creatinine, body mass index, waist-to-hip ratio, chronic infections, fasting glucose, and physical activity (sports score). A 2-sided P value <0.05 was considered significant.

**In Vivo and in Vitro Studies**

Data for in vivo and in vitro studies are presented as the mean±standard error of the mean of ≥3 separate experiments. The analysis was performed using Graphpad Prism V.6 (GraphPad Software) using Student’s t test between 2 groups and 1-way analysis of variance followed by Dunnett’s multiple comparison test for more than 2 groups. A P value <0.05 was considered significant.

**RESULTS**

**Plasma DKK3 Level Is Negatively Correlated With Atherosclerosis in the Population-Based Bruneck Study**

The Bruneck study is a prospective survey on atherosclerosis and its risk factors, as well as protective mechanisms against it. Plasma was collected from a random sample of the general community. A total of 611 samples from the year 2000 and 554 samples from the year 2005 were analyzed for DKK3 concentrations using ELISA. DKK3 levels in both assessments were highly correlated, indicating a low intraindividual variability of a 5-year interval (Spearman’s rank correlation coefficient r=0.500) (online-only Data Supplement Figure I). Population characteristics according to DKK3 tertile groups are depicted in the Table. Age increased across DKK3 tertile groups (P<0.001). After adjustment for age and sex, several standard and emerging cardiovascular risk factors showed association with DKK3 level (creatinine, body mass index, waist-to-hip ratio, and fasting glucose), and all these associations were inverse (Table). It is important to note that the common carotid artery (CCA) IMT, a surrogate marker of early vessel pathology, was reduced in the top DKK3 tertile group (P=0.008) (Figure 1A). A gradual decrease was also seen in the risk of incident atherosclerosis (incident plaques, n=59 out of 259 subjects free of carotid atherosclerosis at baseline; Figure 1B) and carotid artery stenosis (advanced plaques, n=63 out of 332 subjects)
with preexisting carotid atherosclerosis; Figure 1C) across DKK3 tertile groups (P<0.05 each).

We next calculated the odds ratios of incident atherosclerosis and stenosis for a 1-SD unit higher DKK3 level (logistic regression analysis, P=0.035 and 0.004, model 1, online-only Data Supplement Table I) and confirmed the associations to be independent of a broad panel of established and putative vascular risk factors, including those significantly related to DKK3 level in Table (model 2, online-only Data Supplement Table I). Similar findings were obtained with CCA-IMT (online-only Data Supplement Table I). Overall, strong evidence exists of an inverse association between DKK3 level and both early and advanced stages of atherosclerosis.

To scrutinize the correlation between DKK3 and other circulating factors in the blood, granulocyte-colony stimulating factor, matrix metallopeptidase 9, vascular endothelial growth factor, stromal cell-derived factor 1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, and angiogenic cells levels were measured. Stromal cell-derived factor 1 was significantly related to DKK3 (P=0.021, adjusted for age and sex) (online-only Data Supplement Table II).

It is interesting to note that the level of DKK1, another member of the Dickkopf family, showed a significant positive association with CCA-IMT (age- and sex-adjusted regression coefficient [95% confidence interval] for a 1-SD unit higher DKK1 level, 0.031 [0.008–0.054]). The inverse association between DKK3 and CCA-IMT was more pronounced in subjects with high (≥44.1 pmol/L; ie, ≥median) DKK1 level (age- and sex-adjusted regression coefficient [95% confidence interval] for a 1-SD unit higher DKK3 level, -0.018 [-0.037 to 0.001]) than in those with low (<44.1 pmol/L) DKK1 level (age- and sex-adjusted regression coefficient [95% confidence interval] for a 1-SD unit higher DKK3 level, -0.011 [-0.027 to 0.004]), but

| Table. Levels of Study Characteristics According to DKK3 Tertile Groups in the Bruneck Study |
|-----------------------------------------------|-----------------|-----------------|-----------------|----------|----------|
| Variable                                      | Tertile I       | Tertile II      | Tertile III     | P Value* | P Value† |
| Age, y                                        | 61.8±6.6        | 66.7±10.1       | 70.0±10.0       | <0.001  |          |
| Male sex, %                                   | 51.3            | 45.4            | 44.9            | 0.208   |          |
| Systolic blood pressure, mm Hg                | 137.0±17.5      | 141.6±20.6      | 140.5±18.3      | 0.062   | 0.503    |
| Diastolic blood pressure, mm Hg               | 83.9±7.8        | 84.0±8.2        | 83.8±8.9        | 0.911   | 0.781    |
| Hypertension, %                               | 48.3            | 60.3            | 60.0            | 0.018   | 0.860    |
| Urinary albumin, g/dL                         | 23.2±53.7       | 19.4±43.5       | 62.8±282.5      | 0.188   | 0.537    |
| Creatinine, mg/dL                             | 0.85±0.12       | 0.88±0.16       | 0.92±0.29       | 0.001   | 0.004    |
| Leukocyte count, 10⁹/L                        | 6.2±1.6         | 6.1±1.6         | 6.2±1.8         | 0.788   | 0.954    |
| High-sensitivity C-reactive protein, mg/L     | 1.8 (0.9–3.8)   | 1.7 (0.8–3.9)   | 1.8 (0.9–4.6)   | 0.974   | 0.064    |
| Fibrinogen, mg/dL                             | 288.9±56.2      | 287.9±62.3      | 294.1±62.7      | 0.392   | 0.058    |
| Chronic infections, %                         | 14.1            | 24.2            | 31.8            | 0.001   | 0.537    |
| Ferritin, μg/L                                | 124.5±155.1     | 115.3±137.0     | 113.4±110.0     | 0.415   | 0.422    |
| Low-density lipoprotein, mg/dL                | 148.5±40.0      | 151.8±35.8      | 144.8±35.1      | 0.317   | 0.311    |
| High-density lipoprotein, mg/dL               | 57.3±17.0       | 56.4±14.5       | 57.6±14.4       | 0.868   | 0.759    |
| Triglycerides, mg/dL                          | 130 (88–173)    | 121 (92–165)    | 117 (78–157)    | 0.023   | 0.055    |
| Body mass index, kg/m²                        | 26.3±3.7        | 25.2±4.1        | 24.6±4.1        | <0.001 | <0.001   |
| Waist-to-hip ratio, cm/cm                     | 0.92±0.1        | 0.92±0.1        | 0.91±0.1        | 0.043   | 0.003    |
| Physical activity, sports score               | 2.4±0.8         | 2.3±0.7         | 2.3±0.8         | 0.059   | 0.110    |
| Fast glucose, mg/dL                           | 103.7±27.6      | 102.0±25.8      | 99.2±19.1       | 0.063   | 0.001    |
| Hba1C, mmol/mol                               | 4.1±0.7         | 4.1±0.7         | 4.1±0.6         | 0.315   | 0.120    |
| Diabetes mellitus, %                          | 11.9            | 13.8            | 11.8            | 0.799   | 0.073    |
| Homocystein, μmol/L                           | 12.5±12.1       | 13.0±5.0        | 13.7±5.2        | 0.162   | 0.846    |
| Smoking, %                                    | 19.9            | 13.8            | 15.3            | 0.256   | 0.759    |
| Smoking, cigarettes/d                         | 2.6±6.3         | 1.9±5.5         | 1.2±3.7         | 0.005   | 0.243    |
| Alcohol consumption, g/d                      | 24.9±32.2       | 20.9±31.1       | 18.4±23.7       | 0.050   | 0.179    |

*Analyses were unadjusted for age and sex.
†Analyses were adjusted for age and sex.
this interactive effect between DKK1 and DKK3 did not reach statistical significance ($P_{\text{interaction}}=0.17$).

**Deficiency of DKK3 Promotes Atherosclerosis in Mice**

To investigate the role of DKK3 in the development of atherosclerosis, we crossed DKK3-deficient mice\(^\text{35}\) with ApoE\(^{-/-}\) animals to generate DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice (online-only Data Supplement Figure II). As observed with the measurement of atherosclerotic lesions by en face staining (oil red O) of aortas (Figure 2C and online-only Data Supplement Figure III), cross-section-analysis of aortic root samples in male mice fed a normal chow diet for 16 weeks revealed smaller lesion in DKK3\(^{+/+}\)/ApoE\(^{-/-}\) than in DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice (Figure 2A and 2B). Analysis by immunofluorescence showed a significant increase of αSMA staining in lesions from DKK3\(^{+/+}\)/ApoE\(^{-/-}\) mice (Figure 2A and 2D) compared with DKK3\(^{-/-}\)/ApoE\(^{-/-}\), suggesting that these smaller lesions were more stable and less advanced. Furthermore, a staining against CD68 marker revealed a reduction in the number of lesional macrophages in DKK3\(^{+/+}\)/ApoE\(^{-/-}\) mice (Figure 2A and 2D). These data together suggest that DKK3 could have a protective role against atherosclerosis in ApoE\(^{-/-}\) mice.

**DKK3 Deficiency Leads to Endothelial Dysfunction in ApoE\(^{-/-}\) Mice**

It is well established that endothelial cells play an essential role in homeostasis of the vascular wall.\(^\text{36}\) To investigate the possible mechanism associated with the accelerated atherosclerosis in DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice, we first analyzed the integrity of the endothelium by injecting Evans blue in DKK3\(^{+/+}\)/ApoE\(^{-/-}\) and DKK3\(^{+/+}\)/ApoE\(^{-/-}\) mice. The aortas harvested from DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice exhibited a larger blue area, indicating more endothelial damage (Figure 3A). Scanning electron microscopy analysis demonstrated apparent endothelial loss in the aortas from DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice (Figure 3B). To further confirm the impaired endothelial integrity in DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice, immunofluorescence staining of endothelial nitric oxide synthase was performed. A significant decrease in the number of endothelial nitric oxide synthase-positive cells was observed in DKK3\(^{-/-}\)/ApoE\(^{-/-}\) mice (Figure 3B). These data indicate that DKK3-deficient mice display increased endothelium damage, suggesting a protective role of DKK3 on the endothelium in the context of atherosclerosis.

**DKK3 Deficiency Delays Reendothelialization and Aggravates Neointima Formation in Wire-Injured Murine Femoral Arteries**

To test the hypothesis that DKK3 is involved in endothelium recovery after injury, we performed wire injury in femoral arteries of DKK3\(^{-/-}\)/ApoE\(^{-/-}\) and littermate DKK3\(^{+/+}\)/ApoE\(^{-/-}\) mice. Reendothelialization of the arteries was quantified 1 week after injury by en face staining of endothelial nitric oxide synthase. Endothelial cells were recovered by 80% after 1 week in DKK3\(^{+/+}\) mice. In contrast, reendothelialization in DKK3\(^{-/-}\) mice was only ≈50% recovery 1 week after injury (online-only Data Supplement Figure IV). Subsequent neointimal hyperplasia was dramatically aggravated in DKK3\(^{-/-}\) mice 2 and 3 weeks after injury, as demonstrated by increased intima area and reduced lumen area (Figure 4A). To test whether the expres-
sion of DKK3 in hematopoietic cells contributed to this process, we performed bone marrow transplantation experiments. In the wild-type chimaera, DKK3 level in mice serum was significantly increased after 2 weeks despite transplantation with DKK3−/− bone marrow when compared with a nontransplanted wild-type mouse control, indicating that DKK3 is mostly released from nonbone marrow tissues (online-only Data Supplement Figure V). ApoE−/−/DKK3+/+ chimeric mice transplanted with DKK3−/− bone marrow showed comparable neointimal hyperplasia to ApoE−/−/DKK3+/+ mice with wild-type bone marrow 3 weeks after femoral artery wire injury (Figure 4B), indicating that DKK3 expression in hematopoietic-derived cells does not contribute to protection from atherosclerosis and neointima formation postinjury.

Exogenous DKK3 Induces Endothelial Cell Migration

To study whether DKK3 can directly stimulate endothelial cell migration in vitro, both transwell and scratch-wound healing migration assays were performed. Data showed that endothelial cell (HUVEC) migration was significantly induced by human recombinant DKK3.
and peaked at 25 ng/mL (Figure 5A and 5B). Similarly, mouse DKK3 induced mouse lung endothelial cell migration, indicating a conserved mechanism (online-only Data Supplement Figure VIA and VIB). To further investigate whether the glycosylated form of DKK3 contributes to endothelial cell migration, CHO cell lines,
which do not express native DKK3, were transduced with human HA-tagged DKK3 adenovirus to produce the protein. Initially, quantitative polymerase chain reaction and ELISA analysis confirmed DKK3 expression in both CHO cell lysates and their supernatant in a dose-dependent manner (online-only Data Supplement Figure VIC and VID). In addition, Western blot analysis was performed to detect glycosylated DKK3 (65KD) in CHO cell supernatant and deglycosylated DKK3 (50KD) in cell lysate (online-only Data Supplement Figure VIE and VIF). Furthermore, the supernatant of DKK3 adenovirus-induced CHO cells (ADV-DKK3-SN) was utilized in

Figure 4. Increased neointimal lesions in DKK3−/−/ApoE−/− mice after vessel injury. Femoral arteries were wire injured, harvested at different times after surgery, and cross-sectioned for morphological analysis. A, Representative hematoxylin and eosin-stained sections of femoral arteries from DKK3−/−/ApoE−/− and DKK3+/+/ApoE−/− mice (top). Means±SEM from 6 mice for each group of the neointimal area, neointima/media ratio, and luminal area are presented (bottom). *P<0.01, indicating a significant difference between the two groups. B, Representative hematoxylin and eosin-stained sections of femoral arteries from a chimeric mouse, which is DKK3+/+/ApoE−/− mouse receiving DKK3−/−/ApoE−/− or DKK3+/+/ApoE−/− bone marrow after irradiation 3 weeks after vessel injury. The graph shows means±SEM of lesion areas (n=6). No significant difference was noted between the 2 groups. ApoE indicates apolipoprotein E; BMT, bone marrow transplantation; and DKK3, dickkopf-related protein 3.
migration assays to confirm endothelial cell movement (Figure 5C and 5D). Together these results suggested that glycosylated DKK3 present in ADV-DKK3-SN was responsible for the effects observed in endothelial cell migration. To rule out the possibility that residual adenoviral particles present in ADV-DKK3-SN could lead to overexpression of DKK3 in endothelial cells and affect cells’ migration, a quantitative polymerase chain reaction analysis was performed and showed that the increase of DKK3 expression in ADV-DKK3-SN-treated endothelial cells was negligible in comparison with the induction of DKK3 expression in endothelial cells directly transduced with DKK3 adenovirus (online-only Data Supplement Figure VIG through VII). Moreover, endothelial migration on DKK3 protein stimulation was also confirmed by phospho-FAK and paxillin staining (Figure 5E and 5F). A murine subcutaneous Matrigel plug assay showed that DKK3 also induced endothelial cell migration in vivo (online-only Data Supplement Figure VII). In contrast, BrdU cell proliferation and Annexin V apoptosis assays on HUVECs incubated with the recombinant DKK3 protein or ADV-DKK3-SN revealed that

Figure 5. DKK3 can induce endothelial cell migration.
Chemotaxis of human umbilical vein endothelial cells (HUVECs; 1×10⁵ cells/well) across 8.0-μm transwells toward either human recombinant DKK3 (A) or adeno-DKK3-overexpressed CHO supernatant (C) was counted 6 hours after crystal violet staining; 0.1% FBS EBM-2 medium or adeno-CMV null-overexpressed CHO supernatant was used as controls, respectively (n=5, Bars, 100 μm). B and D, Scratch-wound assay was performed on HUVECs. The chemotaxis index of each quantification was defined by the average of 9 fields of view from each well and was presented as fold increase compared with the corresponding controls (n=5). All graphs are shown as mean±SEM. **P<0.01; ***P<0.001. Null-CHO SN indicates adeno-null-overexpressed CHO supernatant; and DKK3-CHO SN, adeno-DKK3-overexpressed CHO supernatant (Bars, 100 μm). E and F, HUVECs were treated with human recombinant DKK3 for indicated time points before immunofluorescence staining of phosphorylated FAK and paxillin. Ctrl indicates control; and p-FAK, phosphorylated FAK (Bars, 50 μm). DKK3 indicates dickkopf-related protein 3.
DKK3 had no effect on cell proliferation or apoptosis (online-only Data Supplement Figure VIII A and VIII B). Taken together, these results support the notion that exogenous DKK3 (especially glycosylated DKK3) significantly induces endothelial cell migration.

**DKK3 Induces Endothelial Cell Migration Through the Wnt Pathways**

β-catenin has been implicated in the regulation of several DKK3 functions through the Wnt/β-catenin signaling pathway. However, in DKK3-treated endothelial cells, β-catenin was not activated as indicated by Western blot analysis or immunofluorescence staining (online-only Data Supplement Figure IX A through IX C). Distinct from a role of the canonical Wnt/β-catenin pathway in the regulation of cell proliferation and development, the noncanonical Wnt pathway is involved in cell polarity and convergent extension movements. Recent studies have indicated that the tyrosine kinase receptor ROR2 plays an important role in the noncanonical Wnt pathway to mediate cell migration. To investigate whether DKK3 induces cell migration through the β-catenin-independent noncanonical Wnt-PCP pathway, we first performed a communoprecipitation analysis, which revealed the binding of DKK3 to ROR2 in endothelial cells after stimulation with either recombinant DKK3 or DKK3-CHO-SN (Figure 6A). This result indicates that transmembrane receptor ROR2 could be a potential binding site for DKK3. As previous studies have demonstrated, members of the Dishevelled family can mediate the Wnt-PCP signaling pathway after activation of ROR2. Hence, we further investigated Dvl1, 2, 3 gene expression levels and found that only Dvl1 displayed a 5-fold reduction on stimulation with DKK3 after 6 hours (Figure 6B). Further immunofluorescence staining of DVL1 revealed its translocation from cytoplasm to the nucleus after DKK3 treatments for 6 hours (Figure 6C).

To study the downstream signaling pathways activated after the binding of DKK3 to ROR2, we measured the level of GTP-Rac1 and GTP-RhoA using pull-down assays. The level of GTP-Rac1 (Figure 6D) but not GTP-RhoA (online-only Data Supplement Figure X) was significantly up-regulated by both recombinant human DKK3 and CHO supernatant, which indicated that Rac1 but not RhoA can be activated by DKK3. A time course Western blotting analysis showed phosphorylation of JNK, and c-jun occurred as early as 5 minutes after treatment with DKK3 in endothelial cells (Figure 6E). siRNA-mediated knockdown of ROR2 in DKK3-treated HUVECs (Figure 6F) significantly reduced downstream DVL1 protein level, JNK, and c-jun phosphorylation (Figure 6G) and inhibited cell migration, therefore placing ROR2 at the top of the signaling cascade mediating DKK3-induced migration (Figure 6J). Successful transfection of plasmids coding for enhanced green fluorescent protein-labeled constitutive Rac1 mutants were shown by quantitative fluorescence-activated cell sorting analysis (online-only Data Supplement Figure X). Moreover, phosphorylation of JNK was markedly up-regulated in response to DKK3 treatment in cells transfected with constitutively active Rac1 but not with constitutively negative mutant (Figure 6H). It is important to note that the migratory abilities of endothelial cells were enhanced in Rac1 constitutively activated cells in response to DKK3 treatment (Figure 6I). Last, migration of endothelial cells toward DKK3 stimulation was markedly reduced in the presence of SP 600125 (an inhibitor of the JNK) (Figure 6K). Therefore, these data indicate that DKK3 induces endothelial cell migration by activating the Wnt-PCP signaling pathway by Rac1-JNK but not RhoA.

**DKK3 Has No Effect on Leukocyte Migration**

Leukocyte migration is critical for atherosclerosis development. Because DKK3 is a potent attractant for endothelial cell migration, it would be crucial to know whether it can also induce leukocyte migration toward the lesion area during atherogenesis. To investigate this issue, the different cell populations contained in peritoneal cells from mice after DKK3 injection into the abdominal cavity were analyzed by fluorescence-activated cell sorting and compared with the saline group (control). Unlike thioglycollate stimulation (positive control), in which cell number was markedly augmented, DKK3 treatment did not significantly increase the number of macrophages, T cells, or B cells in the total peritoneal cell population (online-only Data Supplement Figure XIA and XIB). Furthermore, in vitro migration assay revealed no significant differences in macrophage subpopulation migration toward various concentrations of mouse recombinant DKK3 (online-only Data Supplement Figure XIC). Thus, we conclude that DKK3 does not induce leukocyte recruitment and migration in vitro and in vivo.

**DISCUSSION**

In previous reports, the role of DKK3 as a potential tumor suppressor has been well studied in several human cancers. In recent years, DKK3 was found to act as a potent protector of cardiac hypertrophy by the Wnt signaling pathway, and it also has been associated with stem cell differentiation into vascular smooth muscle cells. In the present study, we found that plasma DKK3 level was inversely and independently associated with CCA-IMT and incident carotid atherosclerosis and stenosis over a 5-year follow-up, suggesting that DKK3 confers protection against both early and advanced stages of atherogenesis.

DKK3, as a secretory glycoprotein, can be released from a variety of tissues in mouse under physiological conditions, which explains the ubiquitous expression of DKK3 in vivo. In our study, we created chimeric mice models to further investigate which source of circulating DKK3 takes part in the protection from atherosclerosis.
Figure 6. DKK3 induces endothelial cell migration by ROR2-Dvl1-Rac1-JNK signaling pathway.

A, Western blot analysis showed the binding of ROR2 and DKK3 after immunoprecipitation of either DKK3 or HA-binding protein in HUVECs stimulated with DKK3 or DKK3-CHO SN. B, The real-time quantitative polymerase chain reaction showed the fold changes in mRNA levels of DVL1, DVL12, and DVL13 after DKK3 treatment. C, Immunofluorescence staining showed the translocation of ROR2 and DVL1 in the nucleus after DKK3 treatments. D, Pull-down assays were performed on HUVECs treated with DKK3 from 1 to 30 minutes to analyze GTP-Rac1 activation. E, Western blot analysis was performed on DKK3-treated HUVECs for the detection of JNK and c-jun phosphorylation and their total expression. F, The gene and protein levels of ROR2 were analyzed by quantitative polymerase chain reaction and fluorescence-activated cell sorting after knockdown by ROR2 siRNA. Western blotting showed the levels of ROR2, DVL1 proteins, and JNK and c-jun phosphorylation in HUVECs after either control siRNA or ROR2 siRNA transfection (G) or phosphorylated JNK and c-jun levels in HUVECs after (Continued)
and neointima formation. In the DKK3−/− chimeric mouse with wild-type bone marrow model, the DKK3 level in serum was barely increased despite transplantation with wild-type bone marrow, indicating that DKK3 is mostly released from nonhematopoietic cells. It is interesting to note that the wild-type chimeric mice with DKK3−/− bone marrow exhibited an even higher level of DKK3, implying that the bone marrow transplantation procedure may induce even more nonhematopoietic cell release of DKK3 into circulation. Given the evidence that endothelial cells express DKK3, the endothelium could be a source of circulating DKK3. When endothelial cells are damaged or dysfunctional, their ability to release DKK3 also might be decreased. Our findings support the notion that the lower levels of DKK3, which were found in the blood of patients with atherosclerosis, could be explained by lower DKK3 release because of endothelial dysfunction. Although the specific cellular and molecular mechanisms of DKK3 release remain unknown, further studies would be needed to clarify how DKK3 is released into the blood.

After being released into the blood, DKK3 may exert its effect on endothelial cells and subsequently the development of atherosclerosis. The endothelium is an indispensable barrier inside the vessel wall, and its integrity has been viewed as a determinant in atherogenesis, especially in the early stages. As a progressive chronic disease, once initiated by risk factors, atherosclerosis provokes a cascade of pathophysiological responses, including postangioplasty neointima formation and restenosis. In our study, different experimental models have confirmed that the endothelium was apparently dysfunctional or damaged in aortas of mice with DKK3 deficiency, suggesting that DKK3 plays a protective role in endothelial integrity. In DKK3−/−/ApoE−/− mice, the atherosclerotic lesion area was smaller compared with DKK3+/+/ApoE−/− mice. In the femoral artery wire injury model, DKK3 displayed properties of protection of endothelial integrity by accelerating the reendothelialization at the early stage as well as reduction of neointima formation at the late phase. The data derived from experimental models provide direct evidence that DKK3 could act as a chemokine-like protein in endothelial migration and thus be protective of atherosclerosis.

In the early stage of atherogenesis, endothelial regeneration is a critical protective mechanism to repair damaged cells and prevent the progression of atherosclerosis. As mentioned previously, an inverse correlation between blood DKK3 level and atherosclerosis in humans and a reduction of arterial reendothelialization after injury in the DKK3−/− mouse model have been observed. It is rational to investigate whether the effect of DKK3 on endothelial cell migration could contribute to endothelial repair. In vitro migration assays showed that exogenous DKK3 significantly induced endothelial cell migration. It was reported that DKK3 is a secreted glycoprotein with 4 potential N-glycosylation sites, and endogenous DKK3 will be glycosylated before its release into the supernatant. In our study, enhanced endothelial migration was induced by secreted and released DKK3 produced by Adeno-DKK3-CHO cells. The glycosylated form of DKK3 protein could be detected in the supernatant, suggesting that glycosylated DKK3 is the main actor on endothelial cell migration. DKK3-induced endothelial migration could play a part in atherogenesis, but other potential effects of DKK3 on the development of the disease are still unknown. Further studies would be needed to understand its roles in the pathogenesis of atherosclerosis.

Previous studies described that DKK3 was expressed in various tumor endothelial cells and that overexpression of DKK3 did not affect proliferation and migration of endothelial colony-forming cells. Similarly, our data also showed that DKK3 within the cell after Adeno-DKK3 transduction did not induce cell migration, indicating that DKK3 may need to interact with its receptor(s) on the cell surface to exert its effects on cell movements. As Wnt signaling pathway inhibitors, DKK family members DKK1, DKK2, and DKK4 were proved to antagonize canonical Wnt/β-catenin signaling by Frizzled family receptors and LRPs/LRP6 coreceptors. It has been demonstrated that DKK1 and DKK2 have important functions in endothelial function, including the role that DKK1 plays in accelerating proinflammatory response and atherosclerosis. In the present study, we found that the DKK1 level in human blood showed a significant positive association with atherosclerosis independently of DKK3 levels. In vitro study of cultured endothelial cells pretreated with DKK3 did induce changes in DKK1-induced interleukin-6 and monocyte chemoattractant protein-1 expression (online-only Data Supplement XII). It is important to note that LRPs or LRPs antagonist sclerostin and draxin did not inhibit DKK3-induced activation of the noncanonical Wnt signaling pathway (online-only Data Supplement XIII). Thus, it seems that DKK3 exerts its effect on

Figure 6 Continued. transfection of constitutive mutants of Rac1 (H). Transwell assay was performed on HUVECs that were either transfected with constitutive mutants of Rac1 (I) or ROR2 siRNA (control) (J) before migration toward DKK3 for 6 hours with either crystal violet staining or direct fluorescence observation of plasmid-transfected cells. K, Transwell assay was performed on HUVECs that migrated toward DKK3 in the presence of JNK inhibitor (SP600125) for 6 hours. All the blots shown are representative of 3 separate experiments. All graphs are shown as mean±SEM (n=3). *P<0.05; **P<0.01; ***P<0.001 (Bars, 100 μm). Ab indicates antibody; act, constitutively active mutant; CHOSN, CHO cells derived-supernatant; CN, supernatant; ctrl, control; D, DKK3; DKK3, dickkopf-related protein 3; DMSO, dimethyl sulfoxide; IgG, immunoglobulin G; neg, constitutively negative mutant; p-c-jun, phosphorylated c-jun; p-JNK, phosphorylated JNK; si-ctrl, control siRNA; si-Ror2, Ror2 siRNA; t-c-jun, total c-jun; t-JNK, total JNK; and wt, constitutively wt mutant.
on endothelial functions related to atherosclerosis independently of other members of DKK family proteins.

In contrast with the other DKK family members, the specific receptors and relevant signaling pathways with which DKK3 interacts remain controversial. Several studies have demonstrated that DKK3 exerts its functions through the canonical Wnt/β-catenin signaling pathway by Kremen and LRPS. In contrast, other studies found no evidence that DKK3 binds to LRPS/6 or Krm1/2 or inhibits the canonical Wnt signaling pathway. In comparison with the canonical Wnt pathway, which is mainly involved in cell proliferation and differentiation, the noncanonical Wnt-planar cell polarity pathway interferes with cell adhesion, motility, and polarity. In the present study, we found that neither β-catenin expression nor its cellular location was changed in endothelial cells after DKK3 treatment. Instead, our data revealed that DKK3 induced cell migration through the activation of GTPase Rac1 but not RhoA and phosphorylation of JNK and c-jun. These results suggest that DKK3-induced cell migration is mediated by a ROR2-Dvl1-Rac1-JNK signaling pathway (online-only Data Supplement XIV).

In summary, in the current study, we have provided the first evidence that DKK3 potentially confers protection against atherosclerosis in human subjects and established that DKK3 affects atherosclerosis progression and neointimal formation in mouse models by influencing reendothelialization. Furthermore, we identified ROR2-Dvl1-Rac1-JNK as the potential signaling pathway that relays DKK3 signal in endothelial cells in vitro to induce cell migration. Taken together, the findings indicate that DKK3 could be an atheroprotective cytokine that might serve as a biomarker of endothelial integrity and repair and a potential therapeutic agent (eg, for improving both early stage reendothelialization and long-term outcome of patients postangioplasty). Although substantial knowledge on vascular risk factors has accumulated over the past years, insights into protective mechanisms are limited and require more extensive studies.

**REFERENCES**

1. Cruciat CM, Niehrs C. Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013;5:a015081. doi: 10.1101/cshperspect.a015081.

2. Karamariti E, Margariti A, Winkler B, Wang X, Hong X, Baban D, Ragoussis J, Huang Y, Han JD, Wong MM, Sag CM, Shah AM, Hu Y, Xu Q. Smooth muscle cells differentiated from reprogrammed embryonic lung fibroblasts through DKK3 signaling are potent for tissue engineering of vascular grafts. Circ Res. 2013;112:1433–1443. doi: 10.1161/CIRCRESAHA.111.300415.

3. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116(Pt 13):2627–2634. doi: 10.1242/jcs.00623.

4. Wang X, Karamariti E, Simpson R, Wang W, Xu Q, Dickkopf homolog 3 induces stem cell differentiation into smooth muscle lineage via ATF6 signalling. J Biol Chem. 2015;290:19844–19852. doi: 10.1074/jbc.M115.641415.

5. de Wilde J, Hulshof MF, Boekschoten MV, de Groot P, Smit E, Mariman EC. The embryonic genes Dkk3, Hoxd8, Hoxd9 and Tbx1 identify muscle types in a diet-independent and fiber-type unrelated way. BMC Genomics. 2010;11:176. doi: 10.1186/1471-2164-11-176.

6. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, Zhang L. Downregulation of Dkk3 activates beta-catenin/TCF-4 signalling in lung cancer. Carcinogenesis. 2008;29:84–92. doi: 10.1093/carcin/bgm267.

7. Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, Chae M, Zhang W, Lee JH. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer. 2009;124:287–297. doi: 10.1002/ijc.23913.

8. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, Zhang L. Downregulation of Dkk3 activates beta-catenin/TCF-4 signalling in lung cancer. Carcinogenesis. 2008;29:84–92. doi: 10.1093/carcin/bgm267.

9. Veeck J, Wild PJ, Fuchs T, Schüßler PJ, Hartmann A, Knöchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009;9:217. doi: 10.1186/1471-2407-9-217.
27. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto M. 2003. J. Pharmacol. Exp. Ther. 305:1022–1030.

28. Kiehl S, Kiehl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis: a population-based study. Arterioscler Thromb. 1993;13:661–668.

29. Xu Q, Kiehl S, Marosi M, Kleindienst R, Oberhollenzer F, Kiehl S, Stulning T, Luef G, Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255–259.

30. Kiehl S, Kiehl S. The natural course of atherosclerosis: part II: vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol. 1999;19:1491–1498.

31. Barrantes Idel B, Montero-Pedrazauela A, Guadano-Ferraz A, Obregon MJ, Martinez de Mena R, Gailus-Durner V, Fuchs H, Franz TJ, Kaladziej S, Klempt M, Hölter S, Raitbol K, Reinhard C, Morra e de Escobar G, Bernal J, Busch D, Wurst W, Wolf E, Schulz H, Shtrom S, Greiner E, Hrabé de Angelis M, Westphal H, Niehrs C. Generation and characterization of dickkopf3 mutant mice. Mol Cell Biol. 2006;26:2317–2326. doi: 10.1128/MCB.26.6.2317-2326.2006.

32. Ha Lat, B. Thrombosis and atherothrombosis. Circulation. 2005;112:2866–2879.

33. Winkler R, Gaido J, Severson G, Wei W, Artymiuk P, Hug M, Tockner K. Dickkopf-Related Protein 3 Is Atheroprotective. J. Biol. Chem. 2004;279:23177–23182. doi: 10.1074/jbc.M408718200.
48. Zhang K, Watanabe M, Kashivakura Y, Li SA, Edamura K, Huang P, Yamaguchi K, Natsu Y, Kobayashi Y, Sakaguchi M, Ochiai K, Yamada H, Takei K, Ueki H, Huh NH, Li M, Kakush H, Na Y, Kumoh H. Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. Int J Oncol. 2010;37:1495–1501.

49. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126. doi: 10.1056/NEJM199901143400207.

50. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168–175.

51. Ross R, Agius L. The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35(Suppl 2):S34–S40.

52. Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. Am J Med. 2003;115:547–553.

53. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res. 2008;78:413–421. doi: 10.1093/cvr/cvn081.

54. Bai X, Wang X, Xu Q. Endothelial damage and stem cell repair in atherosclerosis. Vascul Pharmacol. 2010;52:224–229. doi: 10.1016/j.vph.2010.02.001.

55. Zenzmaier C, Untergasser G, Hermann M, Dinnhofe S, Sampson N, Berger P. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate. 2008;68:540–547. doi: 10.1002/pros.20711.

56. Cheng SL, Shao JS, Behrmann A, Smith C, Krichma K, Towler DA. Vascular smooth muscle LR6 limits arteriosclerotic calcification in diabetic LDLr-/- mice by restraining noncanonical Wnt signals. Circ Res. 2015;117:142–156. doi: 10.1161/CIRCRESAHA.117.306712.

57. Cheng SL, Shao JS, Behrmann A, Krichma K, Towler DA. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33:1679–1689. doi: 10.1161/ATVBHA.113.300647.

58. Min JK, Park H, Choi HI, Kim Y, Pyun BJ, Agrawal V, Song BW, Jeon J, Maeng YS, Rho SS, Shim S, Chai JH, Koo BK, Hong HJ, Yun CO, Choi C, Kim YM, Hwang KC, Kwon YG. The WNT antagonist Dickkop1 promotes angiogenesis in rodent and human endothelial cells. J Clin Invest. 2011;121:1882–1893. doi: 10.1172/JCI42556.

59. Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WI, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, Oie E, Hansson GK, Aukrust P. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1228–1234. doi: 10.1161/ATVBAHA.109.189761.

60. Haog BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 2004;6:2734–2739.

61. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:321–325. doi: 10.1038/35077108.

62. Mao B, Wu W, Davidson G, Manhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417:664–667. doi: 10.1038/nature756.

63. Veeck J, Bektas N, Hartmann A, Kristiansen G, Heinrichs U, Knüchel R, Dahl E. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (Dkk3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res. 2008;10:R82. doi: 10.1186/bcr2151.